MedTrace Logo

Nutritional Oleic Acid Modulation of adIpose Cholesterol Metabolism in Patients Living With Obesity

NCT07027033 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-15

No results posted yet for this study

Summary

Disruption of white adipose tissue (WAT) homeostasis during obesity is central to the development of associated cardiometabolic complications. Dietary supplementation with oleic acid in obese patients can limit these complications. Experimental data, obtained in preclinical models, suggest that the beneficial effects of oleic acid may protect the TAB by increasing cholesterol esterification. The NAMICO study aims to test this hypothesis using TAB biopsies collected from obese patients undergoing bariatric surgery who had previously undergone dietary enrichment with either a conventional oil or an oil rich in oleic acid.

Conditions

  • Obesity
  • Visceral Adipose Tissue
  • White Adipose Tissue Inflammation
  • Subcutaneous Adipose Tissue

Interventions

OTHER

acid-rich sunflower oil oleic acid

Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of sunflower oil rich in oleic acid

OTHER

conventional sunflower oil

Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of conventional sunflower oil

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Marie De Montrichard, PH · Nantes University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2028-07-01
Completion
2028-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07027033 on ClinicalTrials.gov